Biogenvs.Moderna
BIIB vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.2× larger than Moderna by market cap; year to date, Moderna leads (+371.0% vs +23.9%).
Side by side
| BIIB | MRNA | |
|---|---|---|
| Market cap | $31B | $25.2B |
| Price | $220.77 | $158.83 |
| Today | +1.2% | +14.4% |
| Return YTD | +23.9% | +371.0% |
| Return 1Y | +56.6% | +412.1% |
| P/E | 37.2 | — |
| P/S | 3.1 | 11.3 |
| P/B | 1.6 | 3.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More BIIB & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →